Neuralink raised $650 million, received the status of a "breakthrough device" from the FDA and entered the stage of clinical trials

The American company Neuralink, specializing in the development of brain-computer interfaces, has completed a Series E funding round, attracting $650 million in investment. This is reported in the official blog of the company. The funds will be used to develop neuroimplant technologies and expand clinical research.

This is the second major round in the last two years: in 2023, Neuralink received $280 million in Series D funding, to which another $43 million was later added. During this time, the company has demonstrated significant progress in the development of implantable devices that allow you to restore neural connections and control technology using the power of thought.

A key achievement was the status of "breakthrough device", received in May from the FDA-the US Food and Drug Administration. This status is granted to technologies that have the potential to significantly improve the treatment of serious diseases and provides an accelerated process for their development, testing and approval.

Neuralink has already started extensive clinical trials in humans. According to the company, implants were successfully installed in five patients with severe forms of paralysis. At this stage, experts evaluate the security, stability, and efficiency of the system in real-world conditions.

The latest investment deal values the company at about $9 billion (pre-money), which indicates a high level of trust on the part of investors and the market as a whole. Among the participants of the round are both venture funds and technology investors specializing in medtech and bioengineering.

Experts note that the success of Neuralink can open a new era in neurotechnology and medicine, changing the approach to treating neurological disorders and significantly expanding the ability of a person to control external devices directly using the brain.

The company continues to position itself at the intersection of medical neuroscience and high technologies, while the resources received and the support of the FDA allow us to count on accelerated progress towards mass application of developments in the coming years.